Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

Bone mineral content, estimated by single-photon absorptiometry of the forearm, serum values of intact parathyroid hormone (PTH(1-84], osteocalcin, alkaline phosphatase, 1,25-dihydroxycholecalciferol (1,25(OH)2D3), and aluminium were determined during treatment with calcium carbonate (CaCO3) or aluminium hydroxide (Al(OH)3) in 11 dialysis patients participating in a randomised cross-over study.

Each treatment period lasted 6 months.

Who Took Part

According to the abstract, 11 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

The patients were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

Each person switched between Parathyroid Hormone (PTH 1-84) and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Alkaline Phosphatase, Aluminum, Aluminum Hydroxide, Bone Density, Bone Development, Calcinosis and Calcium.

What This Means in Plain Language

The paper is a randomized and crossover study of Parathyroid Hormone (PTH 1-84) in 11 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1991 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.